Suzhou Fushilai Pharmaceutical Co. Ltd. (301258) — Capital Reinvestment Ratio

Latest as of December 2024: 2.24x

Suzhou Fushilai Pharmaceutical Co. Ltd. (301258) has a Capital Reinvestment Ratio of 2.24x as of December 2024, meaning it reinvests 2% of its operating cash flow (CN¥47.07 Million) in capital expenditures (CN¥105.31 Million). See Suzhou Fushilai Pharmaceutical Co. Ltd. free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.

Capital Reinvestment Ratio

2.24x
Capex / Operating Cash Flow

Operating Cash Flow

CN¥47.07 Million
CNY

Capital Expenditures

CN¥105.31 Million
CNY

Data as of

Dec 2024
Most recent filing

Suzhou Fushilai Pharmaceutical Co. Ltd. Capital Reinvestment Ratio (2019–2024)

This chart tracks Suzhou Fushilai Pharmaceutical Co. Ltd.'s Capital Reinvestment Ratio across 6 annual periods.

Annual Capital Reinvestment Ratio for Suzhou Fushilai Pharmaceutical Co. Ltd. (2019–2024)

Year-by-year Capital Reinvestment Ratio for Suzhou Fushilai Pharmaceutical Co. Ltd. from 2019 to 2024. For live market cap and broader valuation context, see Suzhou Fushilai Pharmaceutical Co. Ltd. stock valuation.

Year Reinvestment Ratio Operating CF (CNY) Capital Expenditures YoY Change
2024 2.24x CN¥47.07 Million CN¥105.31 Million ▲ +409.4%
2023 0.44x CN¥94.77 Million CN¥41.62 Million ▲ +32.5%
2022 0.33x CN¥151.19 Million CN¥50.11 Million ▼ -18.0%
2021 0.40x CN¥199.73 Million CN¥80.75 Million ▲ +2.7%
2020 0.39x CN¥166.85 Million CN¥65.69 Million ▼ -16.4%
2019 0.47x CN¥150.55 Million CN¥70.93 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow